Anti-Receptor for Advanced Glycation End Products Therapies as Novel Treatment for Abdominal Aortic Aneurysm
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In Brief Objective: Rupture of abdominal aortic aneurysms (AAA) is a devastating event potentially preventable by therapies that inhibit growth of small aneurysms. Receptor of advanced glycation end products (RAGE) has been implicated in age related diseases including atherosclerosis and Alzheimer. Consequently, we explored whether RAGE may also contribute to the formation of AAAs. Results: Implicating a role for RAGE in AAA, we found the expression of RAGE and its ligand AGE were highly elevated in human aneurysm specimens as compared with normal aortic tissue. In a mouse model of AAA, RAGE gene deletion (knockout) dramatically reduced the incidence of AAA to 1/3 of control (AAAs in 75.0% of controls vs. 25.0% knockouts). Moreover, aortic diameter was markedly reduced in RAGE knockout animals versus controls. As to mechanism, we found that RAGE was coexpressed in AAA macrophages with MMP-9, a promoter of matrix degradation, which is known to induce AAA. In vitro, AGE induced the production of MMP-9 in macrophages in a dose-dependent manner while blocking RAGE signaling with a soluble AGE inhibitor prevented MMP-9 expression. In vivo, RAGE gene deficiency eliminated MMP-9 activity that was prevalent in aneurismal wall of the wild-type mice. Conclusions: RAGE promotes the development of AAA by inducing MMP-9 expression. Blocking RAGE in a mouse aneurysm model has a dramatic inhibitory effect on the formation of aneurysms. These data suggest that larger animal and eventually human trials should be designed to test oral RAGE inhibitors and their potential to prevent progression of small aneurysms. This study shows that the receptor of advanced glycation end products (RAGE) and its ligand advanced glycation end products (AGE) were highly elevated in human aneurysm specimens. In a mouse model of abdominal aortic aneurysms (AAA), RAGE gene knockout dramatically reduced the incidence of AAA. RAGE was coexpressed in AAA macrophages with MMP-9. AGE induced the production of MMP-9 in macrophages. These results suggest that RAGE promotes the development of AAA by inducing MMP-9 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advanced glycation end-products: A review
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001) · Diabetologia · doi:10.1007/s001250051591 · Cited by 2,597 · cited 1×
“Advanced glycation end products (AGEs) are formed from proteins and peptides by nonenzymatic glycoxidation after contact with aldose sugars.(9,10) AGE as well as its receptor (RAGE) has been implicated in disease of the elderly age including atherosclerosis and Alzheimer.”
BackgroundRAGE Mediates a Novel Proinflammatory Axis
Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80801-6 · Cited by 1,864
Self-citationBlockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Self-citationYONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Schleicher, E. D., Wagner, E., & Nerlich, A. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119180 · Cited by 714 · cited 1×
“It is well known that the degradation of AGE is diminished with aging which in turn results in its tissue accumulation.(28) Indeed, several studies have reported that AGE and RAGE are involved in age related diseases such as Alzheimer’s, diabetes and atherosclerosis.”
Background
Cited by
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
“RAGE is expressed on several cell types (monocytes/macrophages [57–59], T-lymphocytes [60–62], endothelial cells [63], dendritic cells [64,65], fibroblasts [66], smooth muscle cells [59,67], neuronal cells, glia cells, chondrocytes [68], keratinocytes [69]) and recognizes a large number of different ligands (AGEs, amy…”
BackgroundCellular signalling of the receptor for advanced glycation end products (RAGE)
Xie, J., Méndez, J. D., Méndez-Valenzuela, V., & Aguilar-Hernández, M. M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.06.013 · Cited by 513
Oxidative Stress in Health and Disease
Reddy, V. P. (2023) · Biomedicines · doi:10.3390/biomedicines11112925 · Cited by 333
Prantner, D., Nallar, S., & Vogel, S. N. (2020) · The FASEB Journal · doi:10.1096/fj.202002136r · Cited by 92
Brown, B. N., Haschak, M. J., Lopresti, S. T., & Stahl, E. C. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.05.001 · Cited by 55
Metadata
- Authors
- Zhang, F., Kent, K. C., Yamanouchi, D., Zhang, Y., Kato, K., Tsai, S., Nowygrod, R., Schmidt, A. M., & Liu, B.
- Venue
- Annals of Surgery
- Published
- 2009-09
- Volume
- 250
- Issue
- 3
- Pages
- 416-423
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2043811790
- Cited by
- 70
- References
- 5
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Receptor for Advanced Glycation End Products Therapies as Novel Treatment for Abdominal Aortic Aneurysm. https://app.cochat.ai/papers/10.1097/sla.0b013e3181b41a18
- The paper
- Zhang, F., Kent, K. C., Yamanouchi, D., Zhang, Y., Kato, K., Tsai, S., Nowygrod, R., Schmidt, A. M., & Liu, B. (2009). Anti-Receptor for Advanced Glycation End Products Therapies as Novel Treatment for Abdominal Aortic Aneurysm. Annals of Surgery. https://doi.org/10.1097/sla.0b013e3181b41a18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.